MDM2 and Miyoshi myopathy: Recently, a compound CMLD010509, which is a synthetic analog of the rocaglate, was found to inhibit the oncogenic translation program in MM cells and in mouse models of MM, targeting MDM2 oncoprotein among other targets (72).